Gluetacs won the 2022 6th Medical Health Investment Excellence Ranking List for the annual biomedical industry

ON：2024-06-04 TAG：GLUETACS THERAPEUTICS

Recently, the High-tech Department of the Lin-gang Special Area Administration released the Notice of China (Shanghai) Pilot Free Trade Zone Lin-gang Special Area Administration on the Publication of the First Batch of High-tech Special Projects in the Year of 2024. According to the evaluation results of the third-party evaluator and the consideration of the special meeting of the Lin-gang Special Area Administration, the project of Key Core Technology R&D Project “Development of Class I New Drug GT919 for the Treatment of hematological malignancies” declared by Gluetacs has been approved, and it will be awarded the matching funding by the Administration.
This batch of special projects is the special support given by the High-tech Department of the Lin-gang Special Area Administration according to the relevant policies, in order to realize the independency, security and control of the supply chain of the frontier industry chain, to support the development of key industries to fill the gaps in the domestic market, to realize the research and development of domestically produced substitutes, and to give special support to the effective breakthroughs in the key core technologies and transformative technologies. A total of 25 projects in the Special Area won.
The special financial support from the Lin-gang Special Area Administrationis a strong driving force for Gluetacs. It not only shows the deep concern and great attention of the relevant departments of Lin-gang Special Area Administration on science and technology innovation, but also provides a solid guarantee for the development of Gluetacs. As an innovative clinical-stage biopharmaceutical technology enterprise specializing in protein degradation technology, Gluetacs has always been committed to technological breakthroughs and scientific research achievement transformation, with deeply aware of the significance of its mission. We deeply understand that the growth of innovative enterprises cannot be separated from the guidance and support of government departments at all levels, and the policy support of the Administration in the field of science and technology innovation has created a favorable innovation environment and provided us with valuable development opportunities.
In the next step, Gluetacs will take this opportunity to give full play to the advantages of innovative enterprises, continue to increase investment in R&D of innovative drugs, cultivate a team of high-tech talents, continuously foster new growth drivers of technological innovation, strive to enhance the core capabilities of enterprises, grasp the infinite possibilities brought by the revolution in the field of medicine, and continue to promote the R&D innovation of protein degraders in a deeper and more practical way to contribute to the enhancement of the people’s health and well-being and the construction of a healthy China.